May 27th, 2015, Beijing, China

Dr. Mingwei Wang, Director of Chinese National Compound Library, and fellows paid a visit to Shenogen on May 25th, 2015. Dr. Kun Meng, Chairman & CEO, together with Dr. Jun Bao (SVP & CBO), Dr. Xiao Shang (SVP), Dr. Qingcong Lin (VP), Dr. Junma Zhou (Executive Director) and Mr. Wenxiong Li (VP), warmly welcomed the guests and held a discussion. 

During the discussion, Dr. Meng introduced Shenogen history and projects. Shenogen has been working on novel anti-cancer drug R&D for nine years. Icaritin, first-in-class small molecule for advanced HCC treatment, is completing Phase II clinical trial. Recently there’s significant progress in MOA study.

Dr. Wang gave high praise towards Shenogen work, and expressed willing of future collaboration. Dr. Wang hopes to build up the Northern Center of Chinese National Compound Library together with Shenogen. It is expected to be an integrated platform for compound-drug screening, small molecule library, antibody library, bioinformatics, ADC and cell-based functional assays. It’s a chance to take advantage of support from Zhongguancun Life Science Park as well as national resources, to combine with company R&D capabilities. 

About Shenogen

Shenogen Pharma Group is a drug discovery and development company based in Beijing, China, that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis. Under the motto of “Better Medicine, Better Life” and a seasoned management team, together with our partners, Shenogen has developed an impressive product pipeline. Our pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. Our lead molecule, icaritin, is currently in Ph II clinical trial for treatment of advanced hepatocellular carcinoma.